Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Esophageal Neoplasms 4Nasopharyngeal Carcinoma 3Carcinoma, Non-Small-Cell Lung 3Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Pancreatic Neoplasms 2Head and Neck Neoplasms 2Stomach Neoplasms 1Resectable Pancreatic Cancer 1Penile Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Glioma 1Glioblastoma 1Esophageal 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms 1Advanced and/or Metastatic Solid Tumours 1Advanced Esophageal 1Adenocarcinoma 1

Interventions

Temozolomide 203Radiotherapy 118Bevacizumab 93Radiation 40Magnetic Resonance Spectroscopy 28Irinotecan 27Carmustine 25Surgical Procedures, Operative 24Lomustine 21Erlotinib Hydrochloride 19Chemotherapy, Adjuvant 18Carboplatin 17temsirolimus 13Drug Therapy 13O(6)-benzylguanine 12Nivolumab 12sargramostim 11Sirolimus 11Radiotherapy, Intensity-Modulated 11Radiotherapy, Conformal 11Sorafenib 10Radiosurgery 10Imatinib Mesylate 10Everolimus 10pembrolizumab 9motexafin gadolinium 9Vorinostat 9Thalidomide 8IL13-PE38 8Gefitinib 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Glioblastoma × nimotuzumab × Clear all
NCT03388372 2018-01-03

Nimotuzumab Plus Radiotherapy With Concomitant and Adjuvant Temozolomide for Cerebral Glioblastoma

Biotech Pharmaceutical Co., Ltd.

Phase 2 Completed
39 enrolled
CNS

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡